These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 9352534)

  • 1. Importance of pre-treatment radiation absorbed dose estimation for radioimmunotherapy of non-Hodgkin's lymphoma.
    Eary JF; Krohn KA; Press OW; Durack L; Bernstein ID
    Nucl Med Biol; 1997 Oct; 24(7):635-8. PubMed ID: 9352534
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Myeloablative 131I-tositumomab radioimmunotherapy in treating non-Hodgkin's lymphoma: comparison of dosimetry based on whole-body retention and dose to critical organ receiving the highest dose.
    Rajendran JG; Gopal AK; Fisher DR; Durack LD; Gooley TA; Press OW
    J Nucl Med; 2008 May; 49(5):837-44. PubMed ID: 18413376
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials.
    Wiseman GA; Kornmehl E; Leigh B; Erwin WD; Podoloff DA; Spies S; Sparks RB; Stabin MG; Witzig T; White CA
    J Nucl Med; 2003 Mar; 44(3):465-74. PubMed ID: 12621016
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-dose (131)I-tositumomab (anti-CD20) radioimmunotherapy for non-Hodgkin's lymphoma: adjusting radiation absorbed dose to actual organ volumes.
    Rajendran JG; Fisher DR; Gopal AK; Durack LD; Press OW; Eary JF
    J Nucl Med; 2004 Jun; 45(6):1059-64. PubMed ID: 15181141
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of radiation dose estimation for myeloablative radioimmunotherapy for relapsed or recurrent mantle cell lymphoma using (131)I tositumomab to that of other types of non-Hodgkin's lymphoma.
    Rajendran J; Gopal A; Durack L; Fisher D; Press O; Eary J
    Cancer Biother Radiopharm; 2004 Dec; 19(6):738-45. PubMed ID: 15665621
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I/II 90Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma.
    Wiseman GA; White CA; Stabin M; Dunn WL; Erwin W; Dahlbom M; Raubitschek A; Karvelis K; Schultheiss T; Witzig TE; Belanger R; Spies S; Silverman DH; Berlfein JR; Ding E; Grillo-López AJ
    Eur J Nucl Med; 2000 Jul; 27(7):766-77. PubMed ID: 10952488
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radioimmunotherapy of non-Hodgkin's lymphoma with 90Y-DOTA humanized anti-CD22 IgG (90Y-Epratuzumab): do tumor targeting and dosimetry predict therapeutic response?
    Sharkey RM; Brenner A; Burton J; Hajjar G; Toder SP; Alavi A; Matthies A; Tsai DE; Schuster SJ; Stadtmauer EA; Czuczman MS; Lamonica D; Kraeber-Bodere F; Mahe B; Chatal JF; Rogatko A; Mardirrosian G; Goldenberg DM
    J Nucl Med; 2003 Dec; 44(12):2000-18. PubMed ID: 14660727
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dosimetric analysis of 177Lu-DOTA-rituximab in patients with relapsed/refractory non-Hodgkin's lymphoma.
    Yadav MP; Singla S; Thakral P; Ballal S; Bal C
    Nucl Med Commun; 2016 Jul; 37(7):735-42. PubMed ID: 26974315
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of nodal regression on radiation dose for lymphoma patients after radioimmunotherapy.
    Hartmann Siantar CL; DeNardo GL; DeNardo SJ
    J Nucl Med; 2003 Aug; 44(8):1322-9. PubMed ID: 12902424
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pre-dosing with lilotomab prior to therapy with
    Stokke C; Blakkisrud J; Løndalen A; Dahle J; Martinsen ACT; Holte H; Kolstad A
    Eur J Nucl Med Mol Imaging; 2018 Jul; 45(7):1233-1241. PubMed ID: 29470615
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A practical methodology for patient release after tositumomab and (131)I-tositumomab therapy.
    Siegel JA; Kroll S; Regan D; Kaminski MS; Wahl RL
    J Nucl Med; 2002 Mar; 43(3):354-63. PubMed ID: 11884495
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bio-effect model applied to 131I radioimmunotherapy of refractory non-Hodgkin's lymphoma.
    Roberson PL; Amro H; Wilderman SJ; Avram AM; Kaminski MS; Schipper MJ; Dewaraja YK
    Eur J Nucl Med Mol Imaging; 2011 May; 38(5):874-83. PubMed ID: 21174088
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patient-specific, 3-dimensional dosimetry in non-Hodgkin's lymphoma patients treated with 131I-anti-B1 antibody: assessment of tumor dose-response.
    Sgouros G; Squeri S; Ballangrud AM; Kolbert KS; Teitcher JB; Panageas KS; Finn RD; Divgi CR; Larson SM; Zelenetz AD
    J Nucl Med; 2003 Feb; 44(2):260-8. PubMed ID: 12571219
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Post therapy imaging in high dose I-131 radioimmunotherapy patients.
    Eary JF; Pollard KR; Durack LD; Bice AN; Lewellen TK; Matthews D; Press OW; Nelp WB; Appelbaum FR; Bernstein I
    Med Phys; 1994 Jul; 21(7):1157-62. PubMed ID: 7968849
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparisons of dosimetric approaches for fractionated radioimmunotherapy of non-Hodgkin lymphoma.
    Ferrer L; Malek E; Bodet-Milin C; Legouill S; Prangère T; Robu D; Jeans S; Tipping J; Huglo D; Carpentier P; Illidge T; Kraeber-Boderé F; Morschhauser F; Bardiès M
    Q J Nucl Med Mol Imaging; 2012 Dec; 56(6):529-37. PubMed ID: 23358406
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 90Y-DOTA-hLL2: an agent for radioimmunotherapy of non-Hodgkin's lymphoma.
    Griffiths GL; Govindan SV; Sharkey RM; Fisher DR; Goldenberg DM
    J Nucl Med; 2003 Jan; 44(1):77-84. PubMed ID: 12515879
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Additional radiation absorbed dose estimates for Zevalin radioimmunotherapy.
    Wiseman GA; Leigh BR; Dunn WL; Stabin MG; White CA
    Cancer Biother Radiopharm; 2003 Apr; 18(2):253-8. PubMed ID: 12804052
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Feasibility and safety of outpatient Bexxar therapy (tositumomab and iodine I 131 tositumomab) for non-Hodgkin's lymphoma based on radiation doses to family members.
    Rutar FJ; Augustine SC; Kaminski MS; Wahl RL; Siegel JA; Colcher D
    Clin Lymphoma; 2001 Dec; 2(3):164-72. PubMed ID: 11779293
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation of marrow dose estimates based on serial pretreatment radiopharmaceutical imaging and blood data with actual marrow toxicity in anti-CD20 yttrium-90 monoclonal antibody radioimmunotherapy of non-Hodgkin's B-cell lymphoma.
    Erwin WD; Spies SM; Kelly ME; Rao P; Eckersberg-Rhodes TE; Nannapaneni M; Groch MW
    Nucl Med Commun; 2001 Feb; 22(2):247-55. PubMed ID: 11258413
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison between 2D and 3D dosimetry protocols in 90Y-ibritumomab tiuxetan radioimmunotherapy of patients with non-Hodgkin's lymphoma.
    Assié K; Dieudonné A; Gardin I; Buvat I; Tilly H; Vera P
    Cancer Biother Radiopharm; 2008 Feb; 23(1):53-64. PubMed ID: 18298329
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.